7.51  0.46 (6.52%)		03-25 16:00
Open: 7 High: 7.8 Volume: 181,151		Pre. Close: 7.05 Low: 6.94 Market Cap: 84(M)

Short term
Mid term
Targets	6-month :	9.27	1-year :	10.83
Resists	First :	7.94	Second :	9.27
Pivot price	6.75
Supports	First :	5.87	Second :	4.59
MAs	MA(5) :	7.32	MA(20) :	6.55
	MA(100) :	4.29	MA(250) :	3.24
MACD	MACD :	0.5	Signal :	0.5
%K %D	K(14,3) :	73.2	D(3) :	76.6
RSI	RSI(14): 67.9
52-week	High :	7.94	Low :	1.33

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NRXS ] has closed below upper band by 18.8%. Bollinger Bands are 79.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	7.8 - 7.84	7.84 - 7.88
Low:	6.83 - 6.86	6.86 - 6.9
Close:	7.45 - 7.51	7.51 - 7.57

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Tue, 24 Mar 2026
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth - Yahoo Finance

Tue, 24 Mar 2026
NeurAxis Shares Rise After Q4 Results Driven by Robust Revenue Expansion - Bitget

Sun, 22 Mar 2026
If You Invested $1,000 in Neuraxis Inc (NRXS) - Stock Titan

Fri, 20 Mar 2026
Neuraxis, Inc.: Fundamental Analysis and Financial Ratings | NRXS | US64134X2018 - marketscreener.com

Thu, 19 Mar 2026
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire

Thu, 19 Mar 2026
Neuraxis (NRXS) expands IB-Stim GI neuromodulation, RED constipation device and IP moat - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.